bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary figure 2 from Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome
Authors: Wolska-Kusnierz Beata , Pastorczak Agata , Fendler Wojciech , Wakulinska Anna , Dembowska-Baginska Bozena , Heropolitanska-Pliszka Edyta , Piątosa Barbara , Pietrucha Barbara , Kałwak Krzysztof , Ussowicz Marek , Pieczonka Anna , Drabko Katarzyna , Lejman Monika , Koltan Sylwia , Gozdzik Jolanta , Styczynski Jan , Fedorova Alina , Miakova Natalia , Deripapa Elena , Kostyuchenko Larysa , Krenova Zdenka , Hlavackova Eva , Gennery Andrew R. , Sykora Karl-Walter , Ghosh Sujal , Albert Michael H. , Balashov Dmitry , Eapen Mary , Svec Peter , Seidel Markus G. , Kilic Sara S. , Tomaszewska Agnieszka , Wiesik-Szewczyk Ewa , Kreins Alexandra , Greil Johann , Buechner Jochen , Lund Bendik , Gregorek Hanna , Chrzanowska Krystyna , Mlynarski Wojciech
Published: April 2023

Overall survival of patients with Nijmegen breakage syndrome depending on the time when they were treated due to malignancies: before and after 2000 year.
Table S4 from Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers
Authors: Zhang Hongyi , Liu Longchao , Zhang Jian , Chen Jiahui , Ye Jianfeng , Shukla Sachet , Qiao Jian , Zhan Xiaowei , Chen Hao , Wu Catherine J. , Fu Yang-Xin , Li Bo
Published: April 2023

NetMHC predicted binding peptide information for TSSK2.
Supplementary Figure 3 from Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome
Authors: Wolska-Kusnierz Beata , Pastorczak Agata , Fendler Wojciech , Wakulinska Anna , Dembowska-Baginska Bozena , Heropolitanska-Pliszka Edyta , Piątosa Barbara , Pietrucha Barbara , Kałwak Krzysztof , Ussowicz Marek , Pieczonka Anna , Drabko Katarzyna , Lejman Monika , Koltan Sylwia , Gozdzik Jolanta , Styczynski Jan , Fedorova Alina , Miakova Natalia , Deripapa Elena , Kostyuchenko Larysa , Krenova Zdenka , Hlavackova Eva , Gennery Andrew R. , Sykora Karl-Walter , Ghosh Sujal , Albert Michael H. , Balashov Dmitry , Eapen Mary , Svec Peter , Seidel Markus G. , Kilic Sara S. , Tomaszewska Agnieszka , Wiesik-Szewczyk Ewa , Kreins Alexandra , Greil Johann , Buechner Jochen , Lund Bendik , Gregorek Hanna , Chrzanowska Krystyna , Mlynarski Wojciech
Published: April 2023

Overall survival of patients with Nijmegen breakage syndrome after cancer diagnosis. Patients who underwent HSCT were marked with an asterix.
Supplementary Legends from Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers
Authors: Zhang Hongyi , Liu Longchao , Zhang Jian , Chen Jiahui , Ye Jianfeng , Shukla Sachet , Qiao Jian , Zhan Xiaowei , Chen Hao , Wu Catherine J. , Fu Yang-Xin , Li Bo
Published: April 2023

Legends for supplementary figures, tables and datasets.
Supplementary Figure 3 from Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
Authors: Rahma Osama E. , Reuss Joshua E. , Giobbie-Hurder Anita , Shoja E Razavi Ghazaleh , Abu-Shawer Osama , Mehra Pooja , Gupta Seema , Simon Richard , Khleif Samir N.
Published: April 2023

Supplementary Figure 3
Supplementary Tables and Figures from Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Authors: Gleeson Jack P. , Nikolovski Ines , Dinatale Renzo , Zucker Mark , Knezevic Andrea , Patil Sujata , Ged Yasser , Kotecha Ritesh R. , Shapnik Natalie , Murray Samuel , Russo Paul , Coleman Jonathan , Lee Chung Han , Stadler Zsofia K. , Hakimi A. Ari , Feldman Darren R. , Motzer Robert J. , Reznik Ed , Voss Martin H. , Chen Ying-Bei , Carlo Maria I.
Published: April 2023

Supplementary Tables and Figures
Supplementary Table S2 from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Authors: Pachynski Russell K. , Kim Eric H. , Miheecheva Natalia , Kotlov Nikita , Ramachandran Akshaya , Postovalova Ekaterina , Galkin Ilia , Svekolkin Viktor , Lyu Yang , Zou Qiong , Cao Dengfeng , Gaut Joseph , Ippolito Joseph E. , Bagaev Alexander , Bruttan Maria , Gancharova Olga , Nomie Krystle , Tsiper Maria , Andriole Gerald L. , Ataullakhanov Ravshan , Hsieh James J.
Published: April 2023

Supplementary Table S2. Staining rounds for prostate tissue specimens. DAPI was imaged at 25 ms after each bleaching round.
Supplementary Figure S4 from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Authors: Pachynski Russell K. , Kim Eric H. , Miheecheva Natalia , Kotlov Nikita , Ramachandran Akshaya , Postovalova Ekaterina , Galkin Ilia , Svekolkin Viktor , Lyu Yang , Zou Qiong , Cao Dengfeng , Gaut Joseph , Ippolito Joseph E. , Bagaev Alexander , Bruttan Maria , Gancharova Olga , Nomie Krystle , Tsiper Maria , Andriole Gerald L. , Ataullakhanov Ravshan , Hsieh James J.
Published: April 2023

Supplementary Figure S4. FLNC expression correlates with superior survival. A, Relative FLNC expression per cell type using a comprehensive gene expression database collected from public sources. B, Box plots showing score of CAF gene expression signature in PCa tumor samples with either the "high" or "low" stromal signature. Samples with |stromal signature| > 1 are shown. C, PFS Kaplan Meier curve showing survival delineated by FLNC expression in PCa (n = 14). P-value was calculated using the two-sided log-rank test.
Supplementary Data from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Authors: Pachynski Russell K. , Kim Eric H. , Miheecheva Natalia , Kotlov Nikita , Ramachandran Akshaya , Postovalova Ekaterina , Galkin Ilia , Svekolkin Viktor , Lyu Yang , Zou Qiong , Cao Dengfeng , Gaut Joseph , Ippolito Joseph E. , Bagaev Alexander , Bruttan Maria , Gancharova Olga , Nomie Krystle , Tsiper Maria , Andriole Gerald L. , Ataullakhanov Ravshan , Hsieh James J.
Published: April 2023

Supplementary Data file with Methods and each Supplementary figure/table linked to legend
Supplementary Figure 2 from Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial
Authors: Vidal Joana , Casadevall David , Bellosillo Beatriz , Pericay Carles , Garcia-Carbonero Rocio , Losa Ferran , Layos Laia , Alonso Vicente , Capdevila Jaume , Gallego Javier , Vera Ruth , Salud Antonieta , Martin-Richard Marta , Nogué Miguel , Cillán Elena , Maurel Joan , Faull Iris , Raymond Victoria , Fernández-Martos Carlos , Montagut Clara
Published: April 2023

Kaplan-Meier estimates of disease-free survival and overall survival according to paired CEA and ctDNA baseline and pre-surgery A. Disease-free survival according to baseline ctDNA and baseline CEA B. Overall survival according to baseline ctDNA and baseline CEA C. Disease-free survival according to pre-surgery ctDNA and pre-surgery CEA D. Overall survival according to pre-surgery ctDNA and pre-surgery CEA pos: positive; neg: negative
Supplementary Figure SF1 from Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma
Authors: Seidlitz Annekatrin , Beuthien-Baumann Bettina , Löck Steffen , Jentsch Christina , Platzek Ivan , Zöphel Klaus , Linge Annett , Kotzerke Jörg , Petr Jan , van den Hoff Jörg , Steinbach Jörg , Krex Dietmar , Schmitz-Schackert Gabriele , Falk Monique , Baumann Michael , Krause Mechthild
Published: April 2023

suppl figure SF1
Supplementary tables from A Clinically Applicable 24-Protein Model for Classifying Risk Subgroups in Pancreatic Ductal Adenocarcinomas using Multiple Reaction Monitoring-Mass Spectrometry
Authors: Son Minsoo , Kim Hongbeom , Han Dohyun , Kim Yoseop , Huh Iksoo , Han Youngmin , Hong Seung-Mo , Kwon Wooil , Kim Haeryoung , Jang Jin-Young , Kim Youngsoo
Published: April 2023

Supplementary table S1 to S14
Supplementary Table S12 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Authors: Wick Antje , Bähr Oliver , Schuler Martin , Rohrberg Kristoffer , Chawla Sant P. , Janku Filip , Schiff David , Heinemann Volker , Narita Yoshitaka , Lenz Heinz-Josef , Ikeda Masafumi , Ando Yuichi , Wick Wolfgang , Steinbach Joachim P. , Burger Michael C. , Wenger Katharina , Lassen Ulrik , Sankhala Kamalesh K. , Roggia Cristiana , Genvresse Isabelle , Munhoz Catya , Rentzsch Christine , Reschke Susanne , Langer Simon , Wagner Markus , Kaulfuss Stefan , Cai Charles , Lagkadinou Eleni , Jeffers Michael , Peña Carol , Tabatabai Ghazaleh
Published: April 2023

Supplementary Table S12. NGS analysis of select tumor-associated genes in archival tumor tissue obtained from a subset of subjects.
Table S4 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Authors: Graillon Thomas , Sanson Marc , Campello Chantal , Idbaih Ahmed , Peyre Matthieu , Peyrière Hadrien , Basset Noémie , Autran Didier , Roche Catherine , Kalamarides Michel , Roche Pierre-Hugues , Fuentes Stéphane , Tabouret Emeline , Barrie Maryline , Cohen Anita , Honoré Stéphane , Boucekine Mohamed , Baumstarck Karine , Figarella-Branger Dominique , Barlier Anne , Dufour Henry , Chinot Olivier Louis
Published: April 2023

Meningioma genes analyses The coding exons and exon-intron boundaries of 13 genes (NF2, AKT1, SMO, KLF4, TRAF7, PIK3CA, SUFU, SMARCB1, SMARCE1, CDKN2A, CDKN2B, PTEN and TERT was sequenced using the Custom QIAseq targeted DNA Panel (Qiagen, Germany) following the manufacturer's instructions. These genes were chosen according the most recent publication on whole genome sequencing or exome sequencing of meningiomas5. TheQIAseq targeted DNA panel utilizes Unique Molecular Indices (UMI)
Supplementary Figure S3 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Authors: Wick Antje , Bähr Oliver , Schuler Martin , Rohrberg Kristoffer , Chawla Sant P. , Janku Filip , Schiff David , Heinemann Volker , Narita Yoshitaka , Lenz Heinz-Josef , Ikeda Masafumi , Ando Yuichi , Wick Wolfgang , Steinbach Joachim P. , Burger Michael C. , Wenger Katharina , Lassen Ulrik , Sankhala Kamalesh K. , Roggia Cristiana , Genvresse Isabelle , Munhoz Catya , Rentzsch Christine , Reschke Susanne , Langer Simon , Wagner Markus , Kaulfuss Stefan , Cai Charles , Lagkadinou Eleni , Jeffers Michael , Peña Carol , Tabatabai Ghazaleh
Published: April 2023

Supplementary Figure S3. Maximum change from baseline in the sum of target lesions and treatment duration ("other tumor types", intrahepatic cholangiocarcinoma, glioblastoma).
Table S3 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Authors: Graillon Thomas , Sanson Marc , Campello Chantal , Idbaih Ahmed , Peyre Matthieu , Peyrière Hadrien , Basset Noémie , Autran Didier , Roche Catherine , Kalamarides Michel , Roche Pierre-Hugues , Fuentes Stéphane , Tabouret Emeline , Barrie Maryline , Cohen Anita , Honoré Stéphane , Boucekine Mohamed , Baumstarck Karine , Figarella-Branger Dominique , Barlier Anne , Dufour Henry , Chinot Olivier Louis
Published: April 2023

PFS6 and PFS12 depending of the in intention-to-treat or per protocole analyses as investigator or central review analyses.
Table S2 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Authors: Graillon Thomas , Sanson Marc , Campello Chantal , Idbaih Ahmed , Peyre Matthieu , Peyrière Hadrien , Basset Noémie , Autran Didier , Roche Catherine , Kalamarides Michel , Roche Pierre-Hugues , Fuentes Stéphane , Tabouret Emeline , Barrie Maryline , Cohen Anita , Honoré Stéphane , Boucekine Mohamed , Baumstarck Karine , Figarella-Branger Dominique , Barlier Anne , Dufour Henry , Chinot Olivier Louis
Published: April 2023

Genes tested in molecular analysis and references
Figure S4 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Authors: Graillon Thomas , Sanson Marc , Campello Chantal , Idbaih Ahmed , Peyre Matthieu , Peyrière Hadrien , Basset Noémie , Autran Didier , Roche Catherine , Kalamarides Michel , Roche Pierre-Hugues , Fuentes Stéphane , Tabouret Emeline , Barrie Maryline , Cohen Anita , Honoré Stéphane , Boucekine Mohamed , Baumstarck Karine , Figarella-Branger Dominique , Barlier Anne , Dufour Henry , Chinot Olivier Louis
Published: April 2023

Study of correlation between SSTR2A receptor expression and growth rate (GR) before and under treatment as with progression. No significant correlation was observed. Immunohistochemical detection of SSTR2A protein was performed on 5 µm thick formalin fixed paraffin embedded (FFPE) tissue sections with Ventana Benchmark XT. The monoclonal SSTR2A antibody (clone UMB1, Abcam) was used at 1/4000 dilution.
Figure S2 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Authors: Graillon Thomas , Sanson Marc , Campello Chantal , Idbaih Ahmed , Peyre Matthieu , Peyrière Hadrien , Basset Noémie , Autran Didier , Roche Catherine , Kalamarides Michel , Roche Pierre-Hugues , Fuentes Stéphane , Tabouret Emeline , Barrie Maryline , Cohen Anita , Honoré Stéphane , Boucekine Mohamed , Baumstarck Karine , Figarella-Branger Dominique , Barlier Anne , Dufour Henry , Chinot Olivier Louis
Published: April 2023

Surface (2D area) growth rate before inclusion expressed in %/3months. Patients with a very high growth rate related to an initial very small tumor were not included in the pretreatement growth rate analysis.
Supplementary Data from Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations
Authors: Sztupinszki Zsofia , Diossy Miklos , Krzystanek Marcin , Borcsok Judit , Pomerantz Mark M. , Tisza Viktoria , Spisak Sandor , Rusz Orsolya , Csabai István , Freedman Matthew L. , Szallasi Zoltan
Published: April 2023

Supplementary Data from Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations
Supplementary Data 2 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Authors: Li Yingming , Yang Rendong , Henzler Christine M. , Ho Yeung , Passow Courtney , Auch Benjamin , Carreira Suzanne , Nava Rodrigues Daniel , Bertan Claudia , Hwang Tae Hyun , Quigley David A. , Dang Ha X. , Morrissey Colm , Fraser Michael , Plymate Stephen R. , Maher Christopher A. , Feng Felix Y. , de Bono Johann S. , Dehm Scott M.
Published: April 2023

Gene Rearrangement Frequencies in WGS Cohort
Figure S2 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
Authors: Vázquez-Borrego Mari C. , Gupta Vandana , Ibáñez-Costa Alejandro , Gahete Manuel D. , Venegas-Moreno Eva , Toledano-Delgado Álvaro , Cano David A. , Blanco-Acevedo Cristóbal , Ortega-Salas Rosa , Japón Miguel A. , Barrera-Martín Ana , Vasiljevic Alexandre , Hill Jason , Zhang Shengwen , Halem Heather , Solivera Juan , Raverot Gérald , Gálvez María A. , Soto-Moreno Alfonso , Paez-Pereda Marcelo , Culler Michael D. , Castaño Justo P. , Luque Raúl M.
Published: April 2023

mRNA and protein expression pattern of key somatostatin receptors in non- functioning pituitary tumors (NFPTs) and normal pituitaries (NPs).
Supplementary Table 3 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
Authors: Chen Xiaoji , Dong Zhao , Hubbell Earl , Kurtzman Kathryn N. , Oxnard Geoffrey R. , Venn Oliver , Melton Collin , Clarke Christina A. , Shaknovich Rita , Ma Ting , Meixiong Gerry , Seiden Michael V. , Klein Eric A. , Fung Eric T. , Liu Minetta C.
Published: April 2023

Supplementary Table 3 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
Supplementary Table 2 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
Authors: Chen Xiaoji , Dong Zhao , Hubbell Earl , Kurtzman Kathryn N. , Oxnard Geoffrey R. , Venn Oliver , Melton Collin , Clarke Christina A. , Shaknovich Rita , Ma Ting , Meixiong Gerry , Seiden Michael V. , Klein Eric A. , Fung Eric T. , Liu Minetta C.
Published: April 2023

Supplementary Table 2 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
Supplementary Test from PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes
Authors: Shaffer Travis , Natarajan Arutselvan , Gambhir Sanjiv S.
Published: April 2023

Supplementary information
Supplementary Figure from Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
Authors: Burgener Justin M. , Zou Jinfeng , Zhao Zhen , Zheng Yangqiao , Shen Shu Yi , Huang Shao Hui , Keshavarzi Sareh , Xu Wei , Liu Fei-Fei , Liu Geoffrey , Waldron John N. , Weinreb Ilan , Spreafico Anna , Siu Lillian L. , de Almeida John R. , Goldstein David P. , Hoffman Michael M. , De Carvalho Daniel D. , Bratman Scott V.
Published: April 2023

Supplementary Figure from Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
Figure S1 from PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes
Authors: Shaffer Travis , Natarajan Arutselvan , Gambhir Sanjiv S.
Published: April 2023

Supplementary Figure 1. The TIGIT plasmid used for transfecting HeLa cells. The mouse TIGIT receptor is expressed under the EF1A promoter while EGFP-Puro is driven by the CMV promoter.
Supplementary Data from Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance
Authors: McKay Rana R. , Kwak Lucia , Crowdis Jett P. , Sperger Jamie M. , Zhao Shuang G. , Xie Wanling , Werner Lillian , Lis Rosina T. , Zhang Zhenwei , Wei Xiao X. , Lang Joshua M. , Van Allen Eliezer M. , Bhatt Rupal S. , Yu Evan Y. , Nelson Peter S. , Bubley Glenn J. , Montgomery R. Bruce , Taplin Mary-Ellen
Published: April 2023

1. Supplementary table 1S describing details of biopsies undergoing WES. 2. Table 2S includes the primers used in the CTC gene expression analysis. 3. Table 3S includes summary of PSA response based on prior treatment. 4. Table 4S includes objective response in the overall cohort and based on patients with measurable and non-measurable disease. 5. Table 5S is the PSA progression and radiographic PFS based on prior lines of treatment. 6. Table 6S is the adverse events in >10% of patients. 7. Table 7S is a listing of the biopsy procedures and outcomes. 8. Table 8S is the frequency of genomic alterations in the baseline and progression samples and PSA response data. 9. Table 9S includes the details for the AR mutations observed in the baseline and progression samples. 10. Figure 1S includes the KM curves for PSA progression and radiographic PFS. 11. Figure 2S includes the Consort Diagram for the study. 12. Figure 3S includes the integrative data of paired biopsy and CTC samples. 13. Figure 4S includes the KM curves for time to PSA progression, radiographic PFS, and overall survival in the CTC biomarker groups.
Supplementary Data from Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
Authors: Burgener Justin M. , Zou Jinfeng , Zhao Zhen , Zheng Yangqiao , Shen Shu Yi , Huang Shao Hui , Keshavarzi Sareh , Xu Wei , Liu Fei-Fei , Liu Geoffrey , Waldron John N. , Weinreb Ilan , Spreafico Anna , Siu Lillian L. , de Almeida John R. , Goldstein David P. , Hoffman Michael M. , De Carvalho Daniel D. , Bratman Scott V.
Published: April 2023

Supplementary Data from Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
Table S2 from Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
Authors: Di Giacomo Anna Maria , Chiarion-Sileni Vanna , Del Vecchio Michele , Ferrucci Pier Francesco , Guida Michele , Quaglino Pietro , Guidoboni Massimo , Marchetti Paolo , Cutaia Ornella , Amato Giovanni , Covre Alessia , Camerini Roberto , Calabrò Luana , Valente Monica , Giannarelli Diana , Mandalà Mario , Maio Michele
Published: April 2023

Clinical outcome of patients with BRAF mutant or wild type melanoma
Figure S2 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
Authors: Paoletti Costanza , Barlow William E. , Cobain Erin F. , Bergqvist Mattias , Mehta Rita S. , Gralow Julie R. , Hortobagyi Gabriel N. , Albain Kathy S. , Pusztai Lajos , Sharma Priyanka , Godwin Andrew K. , Thompson Alastair M. , Hayes Daniel F. , Rae James M.
Published: April 2023

Supplemental Figure 2 Progressionâ€�Free Survival by Treatment Arm for Patients with Prior Adjuvant Tamoxifen (A) Low sTKI (B) High sTKI
Figure S1 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
Authors: Paoletti Costanza , Barlow William E. , Cobain Erin F. , Bergqvist Mattias , Mehta Rita S. , Gralow Julie R. , Hortobagyi Gabriel N. , Albain Kathy S. , Pusztai Lajos , Sharma Priyanka , Godwin Andrew K. , Thompson Alastair M. , Hayes Daniel F. , Rae James M.
Published: April 2023

Supplemental Figure 1 (A) Progression-Free Survival in S0226 (B) Overall Survival in S0226
Supplementary Data from FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Authors: Pulte E. Dianne , Norsworthy Kelly J. , Wang Yaping , Xu Qing , Qosa Hisham , Gudi Ramadevi , Przepiorka Donna , Fu Wentao , Okusanya Olanrewaju O. , Goldberg Kirsten B. , De Claro R. Angelo , Farrell Ann T. , Pazdur Richard
Published: April 2023

Supplementary tables and figures
Supplementary Data from A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes
Authors: Calagua Carla , Ficial Miriam , Jansen Caroline S. , Hirz Taghreed , del Balzo Luke , Wilkinson Scott , Lake Ross , Ku Anson T. , Voznesensky Olga , Sykes David B. , Saylor Philip J. , Ye Huihui , Signoretti Sabina , Kissick Haydn , Sowalsky Adam G. , Balk Steven P. , Einstein David J.
Published: April 2023

Supplementary Data from A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes
Supplementary material and methods from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity
Authors: Sum Eva , Rapp Moritz , Fröbel Philipp , Le Clech Marine , Dürr Harald , Giusti Anna Maria , Perro Mario , Speziale Dario , Kunz Leo , Menietti Elena , Brünker Peter , Hopfer Ulrike , Lechmann Martin , Sobieniecki Andrzej , Appelt Birte , Adelfio Roberto , Nicolini Valeria , Freimoser-Grundschober Anne , Jordaan Whitney , Labiano Sara , Weber Felix , Emrich Thomas , Christen François , Essig Birgit , Romero Pedro , Trumpfheller Christine , Umaña Pablo
Published: April 2023

Additional details on methods used for SPR assays, NanoString RNAseq and cynomolgus monkey studies
Supplementary Table S4c from Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform
Authors: Udayakumar Durga , Zhang Ze , Xi Yin , Dwivedi Durgesh K. , Fulkerson Michael , Haldeman Sydney , McKenzie Tiffani , Yousuf Qurratulain , Joyce Allison , Hajibeigi Asghar , Notgrass Hollis , de Leon Alberto Diaz , Yuan Qing , Lewis Matthew A. , Madhuranthakam Ananth J. , Sibley Robert C. , Elias Roy , Guo Junyu , Christie Alana , McKay Renée M. , Cadeddu Jeffrey A. , Bagrodia Aditya , Margulis Vitaly , Brugarolas James , Wang Tao , Kapur Payal , Pedrosa Ivan
Published: April 2023

DCE-CM vs. Normalized Gene expression
Supplementary Table 1 from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity
Authors: Sum Eva , Rapp Moritz , Fröbel Philipp , Le Clech Marine , Dürr Harald , Giusti Anna Maria , Perro Mario , Speziale Dario , Kunz Leo , Menietti Elena , Brünker Peter , Hopfer Ulrike , Lechmann Martin , Sobieniecki Andrzej , Appelt Birte , Adelfio Roberto , Nicolini Valeria , Freimoser-Grundschober Anne , Jordaan Whitney , Labiano Sara , Weber Felix , Emrich Thomas , Christen François , Essig Birgit , Romero Pedro , Trumpfheller Christine , Umaña Pablo
Published: April 2023

List of antibodies used for flow cytometry
Supplementary Table S4a from Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform
Authors: Udayakumar Durga , Zhang Ze , Xi Yin , Dwivedi Durgesh K. , Fulkerson Michael , Haldeman Sydney , McKenzie Tiffani , Yousuf Qurratulain , Joyce Allison , Hajibeigi Asghar , Notgrass Hollis , de Leon Alberto Diaz , Yuan Qing , Lewis Matthew A. , Madhuranthakam Ananth J. , Sibley Robert C. , Elias Roy , Guo Junyu , Christie Alana , McKay Renée M. , Cadeddu Jeffrey A. , Bagrodia Aditya , Margulis Vitaly , Brugarolas James , Wang Tao , Kapur Payal , Pedrosa Ivan
Published: April 2023

DCE-eNG vs. Normalized Gene expression
Supplementary Table from Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
Authors: Kim Seok-Young , Kim Sang-Min , Lim Sumin , Lee Ji Yeon , Choi Su-Jin , Yang San-Duk , Yun Mi Ran , Kim Chang Gon , Gu Seo Rin , Park Chaewon , Park A-Young , Lim Sun Min , Heo Seong Gu , Kim HyunKi , Cho Byoung Chul
Published: April 2023

Supplementary Table from Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
Supplementary Figure from Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
Authors: Kim Seok-Young , Kim Sang-Min , Lim Sumin , Lee Ji Yeon , Choi Su-Jin , Yang San-Duk , Yun Mi Ran , Kim Chang Gon , Gu Seo Rin , Park Chaewon , Park A-Young , Lim Sun Min , Heo Seong Gu , Kim HyunKi , Cho Byoung Chul
Published: April 2023

Supplementary Figure from Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
Suppl Figure 1 from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival
Authors: Fontana Francesca , Scott Michael J. , Allen John S. , Yang Xiaoxia , Cui Grace , Pan Dipanjan , Yanaba Noriko , Fiala Mark A. , O'Neal Julie , Schmieder-Atteberry Anne H. , Ritchey Julie , Rettig Michael , Simons Kathleen , Fletcher Steven , Vij Ravi , DiPersio John F. , Lanza Gregory M.
Published: April 2023

Supplemental Figure 1 Color
Supplementary fig 5 from Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Authors: Baptista Maria Joao , Baskar Sivasubramanian , Gaglione Erika M. , Keyvanfar Keyvan , Ahn Inhye E. , Wiestner Adrian , Sun Clare
Published: April 2023

Histogram of PD-1 expression in total CD3+, total CD8+, and the most abundant CD8+ clonotype in each patient after expansion with beads or autologous CLL cells.
Supplementary Tables from Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Authors: Baptista Maria Joao , Baskar Sivasubramanian , Gaglione Erika M. , Keyvanfar Keyvan , Ahn Inhye E. , Wiestner Adrian , Sun Clare
Published: April 2023

Supplementary Tables
Figure S2 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Authors: Segal Neil H. , Cercek Andrea , Ku Geoffrey , Wu Abraham J. , Rimner Andreas , Khalil Danny N. , Reidy-Lagunes Diane , Cuaron John , Yang T. Jonathan , Weiser Martin R. , Romesser Paul B. , Stadler Zsofia K. , Varghese Anna M. , Ganesh Karuna , Yaeger Rona , Connell Louise C. , Faleck David , Abou-Alfa Ghassan K. , Mcauliffe Kathleen C. , Vaiskauskas Pamela , Solter Mark L. , Ogle Martinique , Adamow Matthew J. , Holland Aliya , Vedantam Pallavi , Wong Phillip , Merghoub Taha , Vakiani Efsevia , Hollmann Travis J. , Juluru Krishna , Chou Joanne F. , Capanu Marinela , Erinjeri Joseph , Solomon Stephen , Yamada Yoshiya , Kemeny Nancy , Crane Christopher H. , Saltz Leonard B.
Published: April 2023

Flow dot plots
Figure S1 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Authors: Segal Neil H. , Cercek Andrea , Ku Geoffrey , Wu Abraham J. , Rimner Andreas , Khalil Danny N. , Reidy-Lagunes Diane , Cuaron John , Yang T. Jonathan , Weiser Martin R. , Romesser Paul B. , Stadler Zsofia K. , Varghese Anna M. , Ganesh Karuna , Yaeger Rona , Connell Louise C. , Faleck David , Abou-Alfa Ghassan K. , Mcauliffe Kathleen C. , Vaiskauskas Pamela , Solter Mark L. , Ogle Martinique , Adamow Matthew J. , Holland Aliya , Vedantam Pallavi , Wong Phillip , Merghoub Taha , Vakiani Efsevia , Hollmann Travis J. , Juluru Krishna , Chou Joanne F. , Capanu Marinela , Erinjeri Joseph , Solomon Stephen , Yamada Yoshiya , Kemeny Nancy , Crane Christopher H. , Saltz Leonard B.
Published: April 2023

Study design
Supplemental Document A from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Authors: Ellingson Benjamin M. , Sampson John , Achrol Achal Singh , Aghi Manish K. , Bankiewicz Krystof , Wang Chencai , Bexon Martin , Brem Steven , Brenner Andrew , Chowdhary Sajeel , Floyd John R. , Han Seunggu , Kesari Santosh , Randazzo Dina , Vogelbaum Michael A. , Vrionis Frank , Zabek Miroslaw , Butowski Nicholas , Coello Melissa , Merchant Nina , Merchant Fahar
Published: April 2023

Medicenna Imaging Charter for Independent Radiologic Review of MDNA55-05.
Supplementary Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
Authors: Marisa Laetitia , Blum Yuna , Taieb Julien , Ayadi Mira , Pilati Camilla , Le Malicot Karine , Lepage Côme , Salazar Ramon , Aust Daniela , Duval Alex , Blons Hélène , Taly Valérie , Gentien David , Rapinat Audrey , Selves Janick , Mouillet-Richard Sophie , Boige Valérie , Emile Jean-François , de Reyniès Aurélien , Laurent-Puig Pierre
Published: April 2023

supplementary data
Figure S4 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Authors: Ellingson Benjamin M. , Sampson John , Achrol Achal Singh , Aghi Manish K. , Bankiewicz Krystof , Wang Chencai , Bexon Martin , Brem Steven , Brenner Andrew , Chowdhary Sajeel , Floyd John R. , Han Seunggu , Kesari Santosh , Randazzo Dina , Vogelbaum Michael A. , Vrionis Frank , Zabek Miroslaw , Butowski Nicholas , Coello Melissa , Merchant Nina , Merchant Fahar
Published: April 2023

Correlation between mRANO-defined PFS and OS excluding patients with PFS > 120 days. (top) Correlation between radiographic PFS using the mRANO criteria applied to local measurements and OS for patients who died. (bottom) Correlation between radiographic PFS using the mRANO criteria applied to IRF-determined measurements and OS for patients who died. Open circles = patients who were censored (not used in correlation analysis, only for visualization purposes).
Supplemental Figures from Recurrent Human Papillomavirus–Related Head and Neck Cancer Undergoes Metabolic Reprogramming and Is Driven by Oxidative Phosphorylation
Authors: Vyas Avani , Harbison R. Alex , Faden Daniel L. , Kubik Mark , Palmer Drake , Zhang Qing , Osmanbeyoglu Hatice U. , Kiselyov Kirill , Méndez Eduardo , Duvvuri Umamaheswar
Published: April 2023

Supplemental Figures 1-9
Supplementary Tables from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

Supplementary Tables
Supplementary Figure S3 from Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia
Authors: Zhang Hui , Wang Pengfei , Li Zhuoyan , He Yingyi , Gan Wenting , Jiang Hua
Published: April 2023

Supplementary Figure S3. Cytokine profiles of enrolled AML cases treated with CLL1 CAR-T cells. Serum INFγ (A), IL-2 (B), IL-4 (C), IL-10 (D), and TNFα (E) (yellow shaded area represents the reference value) were evaluated using AimPlex BioSciences Human Premixed Multiplex Kits (red line with solid circle, patient 1; blue line with solid square, patient 2; dark green with solid circle, patient 3; purple line with empty square, patient 4).
Supplementary Table 1 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Authors: Bockorny Bruno , Macarulla Teresa , Semenisty Valerya , Borazanci Erkut , Feliu Jaime , Ponz-Sarvise Mariano , Abad David Gutierrez , Oberstein Paul , Alistar Angela , Muñoz Andres , Geva Ravit , Guillén-Ponce Carmen , Fernandez Mercedes Salgado , Peled Amnon , Chaney Marya , Gliko-Kabir Irit , Shemesh-Darvish Liron , Ickowicz Debby , Sorani Ella , Kadosh Shaul , Vainstein-Haras Abi , Hidalgo Manuel
Published: April 2023

Supplementary Table 1
Supplementary Figure 3 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Authors: Bockorny Bruno , Macarulla Teresa , Semenisty Valerya , Borazanci Erkut , Feliu Jaime , Ponz-Sarvise Mariano , Abad David Gutierrez , Oberstein Paul , Alistar Angela , Muñoz Andres , Geva Ravit , Guillén-Ponce Carmen , Fernandez Mercedes Salgado , Peled Amnon , Chaney Marya , Gliko-Kabir Irit , Shemesh-Darvish Liron , Ickowicz Debby , Sorani Ella , Kadosh Shaul , Vainstein-Haras Abi , Hidalgo Manuel
Published: April 2023

Supplementary Figure 3
Table S2 from The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8
Authors: Filipits Martin , Rudas Margaretha , Kainz Verena , Singer Christian F. , Fitzal Florian , Bago-Horvath Zsuzsanna , Greil Richard , Balic Marija , Regitnig Peter , Halper Stefan , Hulla Wolfgang , Egle Daniel , Barron Stephen , Loughman Tony , O'Leary Des , Gallagher William M. , Hlauschek Dominik , Gnant Michael , Dubsky Peter
Published: April 2023

Cross-study analysis between ProsignaÂ® and OncoMasTR
Supplementary Figure 2 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Authors: Bockorny Bruno , Macarulla Teresa , Semenisty Valerya , Borazanci Erkut , Feliu Jaime , Ponz-Sarvise Mariano , Abad David Gutierrez , Oberstein Paul , Alistar Angela , Muñoz Andres , Geva Ravit , Guillén-Ponce Carmen , Fernandez Mercedes Salgado , Peled Amnon , Chaney Marya , Gliko-Kabir Irit , Shemesh-Darvish Liron , Ickowicz Debby , Sorani Ella , Kadosh Shaul , Vainstein-Haras Abi , Hidalgo Manuel
Published: April 2023

Supplementary Figure 2
Table S1 from The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8
Authors: Filipits Martin , Rudas Margaretha , Kainz Verena , Singer Christian F. , Fitzal Florian , Bago-Horvath Zsuzsanna , Greil Richard , Balic Marija , Regitnig Peter , Halper Stefan , Hulla Wolfgang , Egle Daniel , Barron Stephen , Loughman Tony , O'Leary Des , Gallagher William M. , Hlauschek Dominik , Gnant Michael , Dubsky Peter
Published: April 2023

Main clinical and laboratory parameters of trial patients with or without tumor blocks
Supplementary Figure 1 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Authors: Bockorny Bruno , Macarulla Teresa , Semenisty Valerya , Borazanci Erkut , Feliu Jaime , Ponz-Sarvise Mariano , Abad David Gutierrez , Oberstein Paul , Alistar Angela , Muñoz Andres , Geva Ravit , Guillén-Ponce Carmen , Fernandez Mercedes Salgado , Peled Amnon , Chaney Marya , Gliko-Kabir Irit , Shemesh-Darvish Liron , Ickowicz Debby , Sorani Ella , Kadosh Shaul , Vainstein-Haras Abi , Hidalgo Manuel
Published: April 2023

Supplementary Figure 1
Supplementary Legend from The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8
Authors: Filipits Martin , Rudas Margaretha , Kainz Verena , Singer Christian F. , Fitzal Florian , Bago-Horvath Zsuzsanna , Greil Richard , Balic Marija , Regitnig Peter , Halper Stefan , Hulla Wolfgang , Egle Daniel , Barron Stephen , Loughman Tony , O'Leary Des , Gallagher William M. , Hlauschek Dominik , Gnant Michael , Dubsky Peter
Published: April 2023

Supplementary Legend
Figure S1 from The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8
Authors: Filipits Martin , Rudas Margaretha , Kainz Verena , Singer Christian F. , Fitzal Florian , Bago-Horvath Zsuzsanna , Greil Richard , Balic Marija , Regitnig Peter , Halper Stefan , Hulla Wolfgang , Egle Daniel , Barron Stephen , Loughman Tony , O'Leary Des , Gallagher William M. , Hlauschek Dominik , Gnant Michael , Dubsky Peter
Published: April 2023

Additional prognostic value of OncoMasTR to clinical information. The grey bars show the likelihood ratio Ï‡2 of the respective parameter and the orange bars the added likelihood ratio Ï‡2 of the OncoMasTR Molecular Score, OncoMasTR Risk Score, and OncoMasTR Risk Category. The horizontal dashed line represents a statistically significant (P<0.05) increase in likelihood ratio Ï‡2.
Supplementary Table S3 from Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer
Authors: Loree Jonathan M. , Wang Yucai , Syed Muddassir A. , Sorokin Alexey V. , Coker Oluwadara , Xiu Joanne , Weinberg Benjamin A. , Vanderwalde Ari M. , Tesfaye Anteneh , Raymond Victoria M. , Miron Benjamin , Tarcic Gabi , Zelichov Ori , Broaddus Russell R. , Ng Patrick Kwok Shing , Jeong Kang Jin , Tsang Yiu Huen , Mills Gordon B. , Overman Michael J. , Grothey Axel , Marshall John L. , Kopetz Scott
Published: April 2023

Summary of functional validation across four platforms for variants characterized by all assays.
ELECTRONIC SUPPLEMENTARY MATERIALâ€•Online Only from Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
Authors: Hong David S. , Moore Kathleen N. , Bendell Johanna C. , Karp Daniel D. , Wang Judy S. , Ulahannan Susanna V. , Jones Suzanne , Wu Wenjuan , Donoho Gregory P. , Ding Yan , Capen Andrew , Wang Xuejing , Bence Lin Aimee , Patel Manish R.
Published: April 2023

Compiled Supplementary Data
Supplementary Methods from Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer
Authors: Loree Jonathan M. , Wang Yucai , Syed Muddassir A. , Sorokin Alexey V. , Coker Oluwadara , Xiu Joanne , Weinberg Benjamin A. , Vanderwalde Ari M. , Tesfaye Anteneh , Raymond Victoria M. , Miron Benjamin , Tarcic Gabi , Zelichov Ori , Broaddus Russell R. , Ng Patrick Kwok Shing , Jeong Kang Jin , Tsang Yiu Huen , Mills Gordon B. , Overman Michael J. , Grothey Axel , Marshall John L. , Kopetz Scott
Published: April 2023

Supplementary methods providing in depth information about FACT assay, Ba/F3 transformation assay, xenograft in-vivo work and RAS-GTP pulldown experiments.
Supp Figure 5 from Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET
Authors: Garcia-Moure Marc , Gonzalez-Huarriz Marisol , Labiano Sara , Guruceaga Elizabeth , Bandres Eva , Zalacain Marta , Marrodan Lucia , de Andrea Carlos , Villalba Maria , Martinez-Velez Naiara , Laspidea Virginia , Puigdelloses Montse , Gallego Perez-Larraya Jaime , Iñigo-Marco Ignacio , Stripecke Renata , Chan Jennifer A. , Raabe Eric H. , Kool Marcel , Gomez-Manzano Candelaria , Fueyo Juan , Patiño-García Ana , Alonso Marta M.
Published: April 2023

Supp Figure 5 Safety and early effects on immune landscape of Delta-24-RGD in humanized mice bearing CHLA-06 and PFSK-1 supratentorial tumors.
Trial Protocol from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Authors: Weiss Sarah A. , Djureinovic Dijana , Jessel Shlomit , Krykbaeva Irina , Zhang Lin , Jilaveanu Lucia , Ralabate Amanda , Johnson Barbara , Levit Neta Shanwetter , Anderson Gail , Zelterman Daniel , Wei Wei , Mahajan Amit , Trifan Ovid , Bosenberg Marcus , Kaech Susan M. , Perry Curtis J. , Damsky William , Gettinger Scott , Sznol Mario , Hurwitz Michael , Kluger Harriet M.
Published: April 2023

Trial Protocol
Supplemental Figure 2B from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Authors: Weiss Sarah A. , Djureinovic Dijana , Jessel Shlomit , Krykbaeva Irina , Zhang Lin , Jilaveanu Lucia , Ralabate Amanda , Johnson Barbara , Levit Neta Shanwetter , Anderson Gail , Zelterman Daniel , Wei Wei , Mahajan Amit , Trifan Ovid , Bosenberg Marcus , Kaech Susan M. , Perry Curtis J. , Damsky William , Gettinger Scott , Sznol Mario , Hurwitz Michael , Kluger Harriet M.
Published: April 2023

Association between pre-treatment CD8+ T-cell density from available baseline tumor tissue (n=14) and the duration of time on treatment in days.
Supplemental Figure 2A from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Authors: Weiss Sarah A. , Djureinovic Dijana , Jessel Shlomit , Krykbaeva Irina , Zhang Lin , Jilaveanu Lucia , Ralabate Amanda , Johnson Barbara , Levit Neta Shanwetter , Anderson Gail , Zelterman Daniel , Wei Wei , Mahajan Amit , Trifan Ovid , Bosenberg Marcus , Kaech Susan M. , Perry Curtis J. , Damsky William , Gettinger Scott , Sznol Mario , Hurwitz Michael , Kluger Harriet M.
Published: April 2023

Association between pre-treatment CD4+ T-cell density from available baseline tumor tissue (n=14) and the duration of time on treatment in days.
Supplemental Figure 1B from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Authors: Weiss Sarah A. , Djureinovic Dijana , Jessel Shlomit , Krykbaeva Irina , Zhang Lin , Jilaveanu Lucia , Ralabate Amanda , Johnson Barbara , Levit Neta Shanwetter , Anderson Gail , Zelterman Daniel , Wei Wei , Mahajan Amit , Trifan Ovid , Bosenberg Marcus , Kaech Susan M. , Perry Curtis J. , Damsky William , Gettinger Scott , Sznol Mario , Hurwitz Michael , Kluger Harriet M.
Published: April 2023

Waterfall plots demonstrating the percent change in sum of RECIST v1.1 target lesions compared to baseline. Twenty-five out of 26 patients were included; 1 patient withdrew consent and no follow-up imaging was available for review. The waterfall plots are color-coded by (A) best overall response (PR, SD, PD), (B) cohort (1-6), and (C) tumor type (melanoma, RCC, NSCLC). The majority of patients who experienced disease progression on the study had progression in non-target lesions, as denoted by as asterisk (*), and therefore the percent change in tumor from baseline by RECIST is less than the 20% disease progression threshold for multiple patients who had PD.
Supplementary Data from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Fig. S2 Representative flow cytometry data in humans and mice samples. A. Flow cytometry gating strategy for defining Tregs phenotypically by expression of CD3, CD4, CD25 and Foxp3.
Supplementary Data from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Fig. S5 Tregs are increased in the tumor microenvironment.
Supplementary Figure from HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
Authors: Leung Eric , Han Kathy , Zou Jinfeng , Zhao Zhen , Zheng Yangqiao , Wang Ting Ting , Rostami Ariana , Siu Lillian L. , Pugh Trevor J. , Bratman Scott V.
Published: April 2023

Supplementary Figure from HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
Supplementary Data from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Fig. S7 One 5 μg DD injection maximally depleted spleen Tregs 2 days after injection, but the DD IL-2 moiety is not clinically active alone.
Supplementary Data from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Fig. S8 IFN-α plus DD renders tumor dendritic cells less suppressive.
Supplementary Methods from Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer
Authors: Börcsök Judit , Diossy Miklos , Sztupinszki Zsofia , Prosz Aurel , Tisza Viktoria , Spisak Sandor , Rusz Orsolya , Stormoen Dag R. , Pappot Helle , Csabai Istvan , Brunak Søren , Mouw Kent W. , Szallasi Zoltan
Published: April 2023

Description of supplementary materials and methods.
Table S5 from HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor
Authors: Hemming Matthew L. , Coy Shannon , Lin Jia-Ren , Andersen Jessica L. , Przybyl Joanna , Mazzola Emanuele , Abdelhamid Ahmed Amr H. , van de Rijn Matt , Sorger Peter K. , Armstrong Scott A. , Demetri George D. , Santagata Sandro
Published: April 2023

BARX1-/HAND1- GIST
Supplementary Data from KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
Authors: Suzuki Shinichiro , Yonesaka Kimio , Teramura Takeshi , Takehara Toshiyuki , Kato Ryoji , Sakai Hitomi , Haratani Koji , Tanizaki Junko , Kawakami Hisato , Hayashi Hidetoshi , Sakai Kazuko , Nishio Kazuto , Nakagawa Kazuhiko
Published: April 2023

Supplementary Data from KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms